Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 9/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529522 | 0.84 | MELK (0.51) | MELKEGFRERBB2 | |
| SCHEMBL529001 | 0.83 | MELK (0.74) | MELK | |
| SCHEMBL529912 | 0.83 | MELK (0.48) | MELKEGFRERBB2FLT3KDM4E | |
| SCHEMBL530051 | 0.83 | MELK (0.47) | MELKEGFRERBB2 | |
| SCHEMBL529062 | 0.82 | MELK (0.71) | MELKEGFRKDM4EMEN1GAA | |
| SCHEMBL529716 | 0.81 | MELK (0.46) | MELK | |
| SCHEMBL529572 | 0.80 | MELK (0.76) | MELK | |
| SCHEMBL529700 | 0.79 | MELK (0.73) | MELK | |
| SCHEMBL12504780 | 0.76 | EGFR (0.47) | MELKEGFRFLT3 | |
| SCHEMBL529723 | 0.74 | MELK (0.49) | MELKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |